home / stock / azrx / azrx news

AZRX News and Press, AzurRx BioPharma Inc. From 04/15/21

Stock Information
Company Name: AzurRx BioPharma Inc.
Stock Symbol: AZRX
Market: NASDAQ
Website: azurrx.com
Menu
AZRX AZRX Quote AZRX Short AZRX News AZRX Articles AZRX Message Board
Get AZRX Alerts

News, Short Squeeze, Breakout and More Instantly...
AZRX - BioMedNewsBreaks - AzurRx BioPharma Inc. (NASDAQ: AZRX) Shareholder Letter Outlines Program Highlights, Provides Business Update

AzurRx BioPharma (NASDAQ: AZRX) , a clinical stage biopharmaceutical company specializing in the development of targeted, nonsystemic therapies for gastrointestinal (“GI”) diseases, has shared a letter to shareholders from chair, president and CEO James Sapirstein. T...
AZRX - AzurRx Biopharma engages PPD to manage niclosamide clinical trial

AzurRx BioPharma ([[AZRX]] -7.8%) has entered into an agreement with global contract research organization PPD < > for its planned Phase 1b/2a clinical trial evaluating proprietary formulations of micronized niclosamide for grade 1 colitis and diarrhea in oncology patie...

AZRX - AzurRx BioPharma Engages PPD to Manage Clinical Trial for Niclosamide as Treatment for Grade 1 Immune Checkpoint Inhibitor-Associated Colitis

DELRAY BEACH, Fla., April 13, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX ), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestina...

AZRX - Nonhospitalized Long-Haul Coronavirus Patients Susceptible to Cognitive Dysfunction

A group of researchers from the Feinberg School of Medicine at Northwestern University has discovered additional evidence of cognitive dysfunction in many coronavirus patients who were not hospitalized after contracting the infection. The group’s findings were reported in the ȁ...
AZRX - AzurRx BioPharma Initiates Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

“RESERVOIR” trial to evaluate niclosamide’s ability to target SARS-CoV-2 in the GI tract Topline data expected in Q1 2022 DELRAY BEACH, Fla., April 06, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX ), (“AzurRx” or the ...

AZRX - NVVE, UXIN, MVIS and XSPA among midday movers

Gainers: AeroCentury (ACY) +235%.Liberty TripAdvisor (LTRPB) +106%.Uxin (UXIN) +53%.Universe Pharmaceuticals (UPC) +36%.Applied Molecular Transport (AMTI) +31%.Euro Tech Holdings (CLWT) +26%.PLBY Group (PLBY) +25%.Nuvve (NVVE) +24%.Moxian (MOXC) +18%.Sonoma Pharmaceuticals (SNOA) +1...

AZRX - Universe Pharmaceuticals, Applied Molecular Transport leads healthcare gainers; AzurRx BioPharma, BioXcel Therapeutics among major losers

Gainers: Universe Pharmaceuticals UPC +50%, Applied Molecular Transport AMTI +26%, Sonoma Pharmaceuticals (SNOA) +17%, United Therapeutics UTHR +16%, PAVmed (PAVM) +12%.Losers: AzurRx BioPharma (AZRX) -28%, BioXcel Therapeutics (BTAI) -14%,&#x...
AZRX - MicroVision, Telos among premarket losers' pack

AzurRx BioPharma (AZRX) -29% after MS1819 fails in mid-stage cystic fibrosis study.XpresSpa Group (XSPA) -15% on Q4 earnings release.CTI BioPharma (CTIC) -12% after secures $51M capital raise.MicroVision (MVIS) -12%.Boston Omaha (BOMN) -10% on pricing p...

AZRX - AzurRx BioPharma Provides Key Takeaways from Phase 2b OPTION 2 Clinical Trial Topline Results Conference Call

DELRAY BEACH, Fla., March 31, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX ), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestina...

AZRX - AzurRx BioPharma to Report Topline Data from Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis

DELRAY BEACH, Fla., March 31, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX ), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestina...
Previous 10 Next 10